CL2013000715A1 - Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih. - Google Patents

Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih.

Info

Publication number
CL2013000715A1
CL2013000715A1 CL2013000715A CL2013000715A CL2013000715A1 CL 2013000715 A1 CL2013000715 A1 CL 2013000715A1 CL 2013000715 A CL2013000715 A CL 2013000715A CL 2013000715 A CL2013000715 A CL 2013000715A CL 2013000715 A1 CL2013000715 A1 CL 2013000715A1
Authority
CL
Chile
Prior art keywords
methyl
oxazolo
pyrazin
pyrido
difluorophenyl
Prior art date
Application number
CL2013000715A
Other languages
English (en)
Inventor
Deepak B Mundhra
Rennan Pan
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of CL2013000715A1 publication Critical patent/CL2013000715A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; método de tratamiento; y su uso para tratar o prevenir una infección por VIH.
CL2013000715A 2010-09-16 2013-03-15 Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih. CL2013000715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38354110P 2010-09-16 2010-09-16

Publications (1)

Publication Number Publication Date
CL2013000715A1 true CL2013000715A1 (es) 2013-07-05

Family

ID=45832235

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000715A CL2013000715A1 (es) 2010-09-16 2013-03-15 Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih.

Country Status (28)

Country Link
US (7) US20130171214A1 (es)
EP (1) EP2616076B1 (es)
JP (1) JP6231385B2 (es)
KR (1) KR101938662B1 (es)
CN (1) CN103547266B (es)
AU (1) AU2011302030B2 (es)
BR (1) BR112013005907B1 (es)
CA (1) CA2810524C (es)
CL (1) CL2013000715A1 (es)
CY (1) CY1118279T1 (es)
DK (1) DK2616076T3 (es)
EA (1) EA024924B1 (es)
ES (1) ES2594557T3 (es)
HR (1) HRP20161280T1 (es)
HU (1) HUE031336T2 (es)
IL (1) IL225028A (es)
LT (1) LT2616076T (es)
ME (1) ME02520B (es)
MX (1) MX346193B (es)
PL (1) PL2616076T3 (es)
PT (1) PT2616076T (es)
RS (1) RS55222B1 (es)
SI (1) SI2616076T1 (es)
SM (1) SMT201600350B (es)
TW (1) TWI577377B (es)
UA (1) UA108250C2 (es)
WO (1) WO2012037320A2 (es)
ZA (1) ZA201301766B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
KR20150093819A (ko) 2012-12-14 2015-08-18 글락소스미스클라인 엘엘씨 약제 조성물
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20170165271A1 (en) * 2014-02-24 2017-06-15 The Board Of Regents Of The University Of Nebraska Compositions and Methods for the Delivery of Therapeutics
US10092523B2 (en) 2014-09-26 2018-10-09 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
TN2017000232A1 (en) * 2014-12-20 2018-10-19 Troikaa Pharmaceuticals Ltd Injectable formulations of paracetamol
EP4299133A3 (en) * 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
SI3943070T1 (sl) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv, Dolgo delujoče formulacije bedakilina
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
ES2970251T3 (es) * 2018-10-22 2024-05-27 Univ Nebraska Profármacos antivirales y nanoformulaciones de los mismos
WO2020112931A1 (en) 2018-11-29 2020-06-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
CN109646440B (zh) * 2019-01-11 2021-04-20 山东省农业科学院奶牛研究中心 Cabotegravir在制备抗牛传染性鼻气管炎药物中的应用
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
UY38982A (es) * 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
IL295677B1 (en) 2020-02-24 2026-04-01 Gilead Sciences Inc Tetracyclic compounds for the treatment of HIV infection
JP2023532981A (ja) * 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
MX2023000439A (es) * 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
WO2022051198A1 (en) * 2020-09-01 2022-03-10 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
FI4196479T3 (fi) 2021-01-19 2024-01-17 Gilead Sciences Inc Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN115844838B (zh) * 2022-12-01 2023-10-24 浙江萃泽医药科技有限公司 一种可注射的药物组合物
TW202602442A (zh) 2024-03-01 2026-01-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 給藥方案
CN120424092B (zh) * 2025-07-02 2025-09-12 中国人民解放军军事科学院军事医学研究院 布尼亚病毒抑制剂及其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1215599A (fr) * 1958-06-27 1960-04-19 Rhone Poulenc Sa Nouveaux dérivés de l'iminodibenzyle substitués à l'azote par une chaîne pipérazinique et leur préparation
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU723537B2 (en) 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
JP5160005B2 (ja) * 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
US20050084490A1 (en) * 2002-07-09 2005-04-21 Point Therapeutics, Inc. Boroproline compound combination therapy
WO2004018312A1 (en) * 2002-08-21 2004-03-04 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
CA2523035C (en) 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
BRPI0507308A (pt) 2004-01-29 2007-06-26 Baxter Int nanossuspensões de agentes anti-retrovirais para entrega ao sistema nervoso central aumentada
US7985222B2 (en) 2004-04-21 2011-07-26 Medshape Solutions, Inc. Osteosynthetic implants and methods of use and manufacture
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US8129385B2 (en) * 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
WO2007053189A2 (en) * 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
EP1904052A4 (en) 2005-06-17 2008-12-10 Hospira Australia Pty Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF DOCATEXEL
US20070001094A1 (en) 2005-06-29 2007-01-04 Micron Technology, Inc. Infrared filter for imagers
BRPI0707179A2 (pt) * 2006-01-20 2011-04-26 Tibotec Pharm Ltd tratamento de longo termo de infecção por hiv
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP2040671B1 (en) 2006-06-23 2018-01-24 Janssen Sciences Ireland UC Aqueous suspensions of tmc278
SI2175857T1 (sl) * 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
BRPI0821408A2 (pt) * 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
EP2320909B8 (en) * 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
KR101682058B1 (ko) 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2011017395A1 (en) 2009-08-04 2011-02-10 Glaxosmithkline Llc Chemical compounds
US20110152303A1 (en) 2009-12-18 2011-06-23 Glaxosmithkline Llc Chemical Compounds

Also Published As

Publication number Publication date
CN103547266A (zh) 2014-01-29
SI2616076T1 (sl) 2016-11-30
US20170027933A1 (en) 2017-02-02
US20250268893A1 (en) 2025-08-28
ZA201301766B (en) 2016-11-30
PL2616076T3 (pl) 2017-07-31
ME02520B (me) 2017-02-20
EP2616076B1 (en) 2016-07-13
CA2810524C (en) 2018-06-26
ES2594557T3 (es) 2016-12-21
MX2013003037A (es) 2013-09-02
CA2810524A1 (en) 2012-03-22
CY1118279T1 (el) 2017-06-28
EP2616076A2 (en) 2013-07-24
US20130171214A1 (en) 2013-07-04
EA201390233A1 (ru) 2014-03-31
HUE031336T2 (hu) 2017-07-28
BR112013005907B1 (pt) 2021-04-27
TWI577377B (zh) 2017-04-11
US11224597B2 (en) 2022-01-18
HRP20161280T1 (hr) 2016-11-18
EA024924B1 (ru) 2016-11-30
AU2011302030B2 (en) 2015-01-22
JP6231385B2 (ja) 2017-11-15
US20220096469A1 (en) 2022-03-31
US20240307387A1 (en) 2024-09-19
IL225028A (en) 2017-04-30
KR101938662B1 (ko) 2019-01-15
KR20130116254A (ko) 2013-10-23
AU2011302030A1 (en) 2013-04-04
MX346193B (es) 2017-03-10
DK2616076T3 (en) 2016-10-24
JP2014500849A (ja) 2014-01-16
RS55222B1 (sr) 2017-02-28
SMT201600350B (it) 2016-11-10
TW201223529A (en) 2012-06-16
WO2012037320A2 (en) 2012-03-22
US20250017923A1 (en) 2025-01-16
UA108250C2 (uk) 2015-04-10
EP2616076A4 (en) 2015-01-21
CN103547266B (zh) 2016-04-06
US12138264B2 (en) 2024-11-12
LT2616076T (lt) 2016-10-10
BR112013005907A2 (pt) 2016-06-07
US20250017924A1 (en) 2025-01-16
PT2616076T (pt) 2016-09-30
WO2012037320A3 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
CL2013000715A1 (es) Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih.
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
PE20140255A1 (es) Tableta dispersable en forma oral
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CL2013000399A1 (es) Compuestos derivados de ester de acido boronico; composicion farmaceutica; recipiente esteril; metodo de preparacion; y su uso para el tratamiento o la prevencion de una infeccion bacteriana.
BR112013011737A2 (pt) composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
CL2013000718A1 (es) Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades.
CL2012003723A1 (es) Compuestos derivados de acido 2-quinolinil-acetico; composicion farmaceutica; y uso en el tratamiento del vih y sida.
BR112017014599A2 (pt) dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
CL2014000732A1 (es) Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
NI200700222A (es) N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas.
BRPI0921519A8 (pt) Forma de dosagem de fármaco sufentanil sólida embalada e método para prevenir a degradação oxidativa da referida forma de dosagem
BRPI0922806B8 (pt) composição farmacêutica oral compreendendo bendamustina
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
AR082030A1 (es) Composiciones farmaceuticas topicas que comprenden flurbiprofeno, uso y metodo de tratamiento
CO2017013317A2 (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma